US20030045503A1 - Composition for the relief of joint pain and myofascial pain and method of preparing same - Google Patents
Composition for the relief of joint pain and myofascial pain and method of preparing same Download PDFInfo
- Publication number
- US20030045503A1 US20030045503A1 US10/261,207 US26120702A US2003045503A1 US 20030045503 A1 US20030045503 A1 US 20030045503A1 US 26120702 A US26120702 A US 26120702A US 2003045503 A1 US2003045503 A1 US 2003045503A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- glucosamine
- chondroitin
- base
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- This invention relates to a topically applied composition for the treatment of joint pain and myofascial pain, a process for preparing the composition, and a method of treating joint pain and, myofascial pain using the composition.
- Joint pain and myofascial pain can be caused by arthritis, cartilage injury or disease, and other sources. Patients can find such pain to be debilitating, and have used a variety of treatments for relief of pain, including formulations administered orally, parenterally, and topically.
- a popular form of treatment for joint pain and myofascial pain is the topical application of pain relieving ointments which contain menthol.
- Formulations for topical application can either be water-based or substantially anhydrous.
- anhydrous (i.e. oil-based) formulations are preferable because anhydrous formulations will not evaporate like those containing water or alcohol.
- Anhydrous formulations therefore, are easier to use in massaging applications.
- glucosamine and chondroitin in topical formulations is also known. However, it was not known to use them together in a substantially anhydrous base. In fact, until now, it has not been possible to prepare a stable, substantially anhydrous, topical formulation containing both a chondroitin and a glucosamine. Moreover, it was not known to use glucosamine and chondroitin in combination with an analgesic in a formulation for topical application
- One object of this invention is to provide an stable, topical composition for the temporary treatment of joint pain and myofascial pain.
- a further object of this invention is to provide an improved method for the temporary treatment of joint pain and myofascial pain.
- a further object of this invention is to provide a method for preparing a stable, topical formulation for the temporary treatment of joint pain and myofascial pain comprising chondroitin and glucosamine.
- a topical formulation comprising a glucosamine compound and a chondroitin compound in an anhydrous base, wherein the formulation is stable, as defined below, for ten days or more.
- a further object of this invention is a topical formulation comprising a glucosamine compound and a chondroitin compound in combination with an analgesic.
- chondroitin means a compound selected from chondroitin, chondroitin salts, and mixtures thereof
- glucosamine means a compound selected from the group consisting of glucosamine, glucosamine salts and mixtures thereof.
- the preferred species of glucosamine is glucosamine sulfate, while the preferred species of chondroitin is chondroitin sulfate.
- stable what is meant is that the formulation, when stored at a temperature of 104° F. at a relative humidity of 75%, remains uniformly mixed, so that none of the components separates from the rest of the formulation. Thus, the overall composition remains unchanged and, the glucosamine and chondroitin are evenly distributed throughout the formulation.
- the compositions according to the invention are stable for at least 10 days, preferably are stable for at least 30 days, and most preferably are stable for at least 60 days. Ideally, the composition is stable for at least 90 days.
- substantially anhydrous what is meant is that the total water content of the formulation is not more than 0.2% by weight.
- base means a mixture of all of the components of the formulation of the invention except for the chondroitin and the glucosamine. Unless otherwise noted, all percentages are by, weight relative to the total weight of the formulation.
- the base is preferably substantially anhydrous, but may otherwise comprise those materials commonly used by those of ordinary skill in the art of preparing topical formulations.
- anhydrous lanolin, copaiba oil, lavender oil, citrus oil, eucalyptus oil, and cannola oil can be used to make up the anhydrous base. Pain relieving materials, such as menthol, capsaicin, and methyl salicylate may also be used in the base.
- the base can include colorants, fragrances, and preservatives, as will be known to those of ordinary skill in this art.
- the total amount of the base material will range from about 70% to about 99.9% by weight. Preferably, the total amount will be from about 97% to 99% by weight.
- the formulation will also include a pain relieving material, in amounts from about 3% to about 25% by weight, preferably from about 10% to about 20% by weight, most preferably about 16% by weight.
- the base can include preservatives and coloring agents. Generally the total amount of such additives would not exceed 5% by weight of the total formulation. However, the base preferably does not contain such additives.
- the topical formulation according to the invention comprises anhydrous lanolin, menthol, eucalyptus oil, citrus oil, copaiba oil, and lavender oil, as well as chondroitin sulfate and glucosamine sulfate.
- Glucosamine and chondroitin are each present in amounts from about 0.01% to about 3% by weight.
- the glucosamine and chondroitin are each present in amounts from about 0.05% to about 2% by weight.
- glucosamine and chondroitin are each present in amounts from about 0.1% to about 1.5% by weight.
- compositions according to the invention which include both glucosamine and chondroitin, are smoother and are superior emollients than similar formulations without the glucosamine and the chondroitin.
- a further embodiment of the invention is a topical formulation comprising an analgesic, chondroitin, and glucosamine.
- the base need not be substantially anhydrous.
- Such a topical formulation is novel and provides increased benefits with respect to the penetration and effectiveness of the analgesic as compared with prior art topical formulations.
- the inventors have found a novel method of preparing the formulation of the invention. Specifically, the components of the base are mixed together in conventional fashion, for example by using a medium speed agitator. This base is then heated to a temperature of about 120° F. to about 160° F., preferably from about 130° F. to about 150° F., most preferably about 140° F. Generally, the mixture is kept at this elevated temperature for about 1 to about 2 hours, though it can be for a different amount of time. The mixture is then allowed to cool to a temperature of about 50° F. to about 90° F., preferably from about 60° F. to about 80° F., most preferably about 72° F. The mixture is allowed to stand at this temperature for a period of at least 2 hours, more preferably at least 8 hours, and most preferably at least 12 hours. Ideally, the mixture will be allowed to stand for about 24 hours.
- the chondroitin and glucosamine are mixed in.
- This mixing can be accomplished using a medium speed agitator.
- the mixing in of the chondroitin and the glucosamine continues for a period of about 1 to about 10 hours, preferably for about 2 hours.
- the mixing must continue for at least as long as is necessary to achieve a uniform distribution of the glucosamine and the chondroitin in the formulation.
- the formulation is then allowed to stand for at least 1 hour, preferably for at least 3 hours, and most preferably for at least 4 hours.
- the formulation is then mixed for an additional period of about 1 to about 10 hours, preferably for about 2 hours.
- Another embodiment of this invention is a method for treating joint pain and/or myofascial pain comprising the application of an effective amount of the anhydrous formulation described above to the area of the skin overlying the painful joint or soft tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A stable, formulation comprising glucosamine and chondroitin compounds in a base which can be used for topical application to relieve joint pain and myofascial pain. A method of preparing the composition by adding the glucosamine and chondroitin after the rest of the components of the formulation have been mixed and heated is also disclosed.
Description
- This invention relates to a topically applied composition for the treatment of joint pain and myofascial pain, a process for preparing the composition, and a method of treating joint pain and, myofascial pain using the composition.
- Joint pain and myofascial pain can be caused by arthritis, cartilage injury or disease, and other sources. Patients can find such pain to be debilitating, and have used a variety of treatments for relief of pain, including formulations administered orally, parenterally, and topically. A popular form of treatment for joint pain and myofascial pain is the topical application of pain relieving ointments which contain menthol.
- Formulations for topical application can either be water-based or substantially anhydrous. For many applications, anhydrous (i.e. oil-based) formulations are preferable because anhydrous formulations will not evaporate like those containing water or alcohol. Anhydrous formulations, therefore, are easier to use in massaging applications.
- The use of chondroitin and glucosamine in the repair of connective tissue is well known. For example, U.S. Pat. Nos. 5,587,363 and 5,364,845 describe the use of a mixture of glucosamine and chondroitin in an oral formulation for the repair of connective tissue.
- The use of glucosamine and chondroitin in topical formulations is also known. However, it was not known to use them together in a substantially anhydrous base. In fact, until now, it has not been possible to prepare a stable, substantially anhydrous, topical formulation containing both a chondroitin and a glucosamine. Moreover, it was not known to use glucosamine and chondroitin in combination with an analgesic in a formulation for topical application
- One object of this invention is to provide an stable, topical composition for the temporary treatment of joint pain and myofascial pain.
- A further object of this invention is to provide an improved method for the temporary treatment of joint pain and myofascial pain.
- A further object of this invention is to provide a method for preparing a stable, topical formulation for the temporary treatment of joint pain and myofascial pain comprising chondroitin and glucosamine.
- These and other objects are achieved by a topical formulation comprising a glucosamine compound and a chondroitin compound in an anhydrous base, wherein the formulation is stable, as defined below, for ten days or more.
- A further object of this invention is a topical formulation comprising a glucosamine compound and a chondroitin compound in combination with an analgesic.
- As used in this specification, the term “chondroitin” means a compound selected from chondroitin, chondroitin salts, and mixtures thereof, and glucosamine means a compound selected from the group consisting of glucosamine, glucosamine salts and mixtures thereof. The preferred species of glucosamine is glucosamine sulfate, while the preferred species of chondroitin is chondroitin sulfate.
- By “stable,” what is meant is that the formulation, when stored at a temperature of 104° F. at a relative humidity of 75%, remains uniformly mixed, so that none of the components separates from the rest of the formulation. Thus, the overall composition remains unchanged and, the glucosamine and chondroitin are evenly distributed throughout the formulation. The compositions according to the invention are stable for at least 10 days, preferably are stable for at least 30 days, and most preferably are stable for at least 60 days. Ideally, the composition is stable for at least 90 days.
- By “substantially anhydrous,” what is meant is that the total water content of the formulation is not more than 0.2% by weight. As used in this application, the term “base” means a mixture of all of the components of the formulation of the invention except for the chondroitin and the glucosamine. Unless otherwise noted, all percentages are by, weight relative to the total weight of the formulation.
- The base, is preferably substantially anhydrous, but may otherwise comprise those materials commonly used by those of ordinary skill in the art of preparing topical formulations. For example, anhydrous lanolin, copaiba oil, lavender oil, citrus oil, eucalyptus oil, and cannola oil, and other materials can be used to make up the anhydrous base. Pain relieving materials, such as menthol, capsaicin, and methyl salicylate may also be used in the base. In addition, the base can include colorants, fragrances, and preservatives, as will be known to those of ordinary skill in this art.
- Generally, the total amount of the base material will range from about 70% to about 99.9% by weight. Preferably, the total amount will be from about 97% to 99% by weight. Preferably, the formulation will also include a pain relieving material, in amounts from about 3% to about 25% by weight, preferably from about 10% to about 20% by weight, most preferably about 16% by weight. As noted above, the base can include preservatives and coloring agents. Generally the total amount of such additives would not exceed 5% by weight of the total formulation. However, the base preferably does not contain such additives.
- In a preferred embodiment, the topical formulation according to the invention comprises anhydrous lanolin, menthol, eucalyptus oil, citrus oil, copaiba oil, and lavender oil, as well as chondroitin sulfate and glucosamine sulfate.
- Glucosamine and chondroitin are each present in amounts from about 0.01% to about 3% by weight. Preferably, the glucosamine and chondroitin are each present in amounts from about 0.05% to about 2% by weight. Most preferably glucosamine and chondroitin are each present in amounts from about 0.1% to about 1.5% by weight.
- It has been found that the combination of anhydrous lanolin with chondroitin and glucosamine produces unexpected results in effectuating the penetration of the pain relieving agent, such as menthol, into the skin. The combination of lanolin, chondroitin and glucosamine has also been found to have unexpectedly good moisturizing effects on the skin. Moreover, the compositions according to the invention, which include both glucosamine and chondroitin, are smoother and are superior emollients than similar formulations without the glucosamine and the chondroitin.
- A further embodiment of the invention is a topical formulation comprising an analgesic, chondroitin, and glucosamine. In this embodiment of the invention, the base need not be substantially anhydrous. Such a topical formulation is novel and provides increased benefits with respect to the penetration and effectiveness of the analgesic as compared with prior art topical formulations.
- The inventors have found a novel method of preparing the formulation of the invention. Specifically, the components of the base are mixed together in conventional fashion, for example by using a medium speed agitator. This base is then heated to a temperature of about 120° F. to about 160° F., preferably from about 130° F. to about 150° F., most preferably about 140° F. Generally, the mixture is kept at this elevated temperature for about 1 to about 2 hours, though it can be for a different amount of time. The mixture is then allowed to cool to a temperature of about 50° F. to about 90° F., preferably from about 60° F. to about 80° F., most preferably about 72° F. The mixture is allowed to stand at this temperature for a period of at least 2 hours, more preferably at least 8 hours, and most preferably at least 12 hours. Ideally, the mixture will be allowed to stand for about 24 hours.
- Following the waiting period, the chondroitin and glucosamine are mixed in. This mixing can be accomplished using a medium speed agitator. The mixing in of the chondroitin and the glucosamine continues for a period of about 1 to about 10 hours, preferably for about 2 hours. The mixing must continue for at least as long as is necessary to achieve a uniform distribution of the glucosamine and the chondroitin in the formulation. The formulation is then allowed to stand for at least 1 hour, preferably for at least 3 hours, and most preferably for at least 4 hours. The formulation is then mixed for an additional period of about 1 to about 10 hours, preferably for about 2 hours.
- Another embodiment of this invention is a method for treating joint pain and/or myofascial pain comprising the application of an effective amount of the anhydrous formulation described above to the area of the skin overlying the painful joint or soft tissue.
Claims (23)
1. A topical formulation comprising glucosamine and chondroitin in a substantially anhydrous base, wherein the formulation is stable for at least 10 days.
2. The formulation of claim 1 , wherein the glucosamine is present in the form of glucosamine sulfate.
3. The formulation of claim 1 , wherein the chondroitin is present in the form of chondroitin sulfate.
4. The formulation of claim 1 , wherein the base comprises anhydrous lanolin.
5. The formulation of claim 4 , wherein the base further comprises menthol.
6. The formulation of claim 1 , wherein the base comprises menthol.
7. The formulation of claim 1 , wherein the formulation is stable for at least 30 days.
8. The formulation of claim 1 , wherein the compound is stable for at least 60 days.
9. The composition of claim 1 , wherein the chondroitin and the glucosamine are each independently present in an amount from about 0.01% to about 3% by weight.
10. The composition of claim 9 , wherein the chondroitin and the glucosamine are each independently present in an amount about 0.05% to about 2% by weight.
11. The composition of claim 10 , wherein the chondroitin and the glucosamine are each independently present in an amount from about 0.1% to about 1.5% by weight.
12. A process for preparing a substantially anhydrous topical formulation comprising a base, chondroitin, and glucosamine which is stable for at least 10 days, the process comprising the following steps:
(a) mixing the components of the base, and heating the base to a temperature from about 120° F. to about 160° F.;
(b) letting the base from step (a) stand for a period of at least two hours at a temperature of about 50° F. to about 90° F.;
(c) mixing the chondroitin and the glucosamine into the mixture from step (b).
13. The process according to claim 12 , wherein the mixture from step (c) is allowed to stand for a period of at least 1 hour, followed by additional mixing.
14. The process according to claim 12 , wherein the mixing of step (a) occurs at a temperature from about 130° to 150° F.
15. The process according to claim 14 , wherein the mixing of step (a) occurs at a temperature of about 140° F.
16. The process according to claim 12 , wherein step (b) occurs at a temperature from about 60° F. to about 80° F.
17. The process according to claim 12 , wherein, in step (b), the base from step (a) is allowed to stand for at least 8 hours.
18. The process according to claim 17 , wherein, in step (b), the base from step (a) is allowed to stand for at least 12 hours.
19. The process according to claim 13 , wherein the mixture from step (c) is allowed to stand for about 2 hours, followed by about 2 hours of additional mixing.
20. A formulation for topical formulation comprising an analgesic, chondroitin, and glucosamine.
21. The formulation of claim 20 , wherein the analgesic is menthol.
22. The formulation of claim 21 , wherein the chondroitin is present in the form of chondroitin sulfate, and the glucosamine is present in the form of glucosamine sulfate.
23. A method for treating joint pain or myofascial pain comprising the application of an effective amount of the composition of claim 1 to areas of the skin overlying the painful joint or soft tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/261,207 US20030045503A1 (en) | 1998-12-23 | 2002-09-30 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21941298A | 1998-12-23 | 1998-12-23 | |
US09/410,868 US6482401B1 (en) | 1998-12-23 | 1999-10-01 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
US10/261,207 US20030045503A1 (en) | 1998-12-23 | 2002-09-30 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,868 Division US6482401B1 (en) | 1998-12-23 | 1999-10-01 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030045503A1 true US20030045503A1 (en) | 2003-03-06 |
Family
ID=22819170
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,868 Expired - Fee Related US6482401B1 (en) | 1998-12-23 | 1999-10-01 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
US10/261,207 Abandoned US20030045503A1 (en) | 1998-12-23 | 2002-09-30 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,868 Expired - Fee Related US6482401B1 (en) | 1998-12-23 | 1999-10-01 | Composition for the relief of joint pain and myofascial pain and method of preparing same |
Country Status (1)
Country | Link |
---|---|
US (2) | US6482401B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007808B1 (en) * | 2004-10-12 | 2007-02-27 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Preparation for the treatment of joint diseases |
EA007809B1 (en) * | 2004-10-12 | 2007-02-27 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Preparation for the treatment of joint diseases |
WO2007087344A3 (en) * | 2006-01-25 | 2007-12-13 | Taro Pharmaceuticals Usa Inc | Anti-histamine compositions and use thereof |
WO2009007660A1 (en) | 2007-07-04 | 2009-01-15 | Mathieu Borge | Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146587A1 (en) * | 2003-01-29 | 2004-07-29 | James Spicer | Topical composition for relief of pain and minor skin irritations |
US7423064B2 (en) * | 2004-09-24 | 2008-09-09 | Olatec Industries, Llc | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
RU2260432C1 (en) * | 2004-10-12 | 2005-09-20 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Agent for treatment of articulation diseases |
EP2070525A1 (en) * | 2007-12-11 | 2009-06-17 | DSM IP Assets B.V. | Compositions comprising Magnolol and/or Honokiol and chondroitin and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
IT1402382B1 (en) † | 2010-09-09 | 2013-09-04 | Ibsa Inst Biochimique Sa | HYBRID COOPERATIVE COMPLEX HYALURONIC ACID |
ITMI20121316A1 (en) * | 2012-07-27 | 2014-01-28 | Altergon Sa | CONDROTIC COMPLEXES FOR TRANSCUTANEOUS ABSORPTION |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473551A (en) * | 1982-08-23 | 1984-09-25 | Faxon Pharmaceuticals, Inc. | Anti-inflammatory composition |
US4702916A (en) | 1985-12-03 | 1987-10-27 | Warner-Lambert Company | Analgesic stick compositions |
US5178881A (en) * | 1991-04-12 | 1993-01-12 | Leonard Mackles | Anhydrous topical compositions which dry rapidly on contact |
US5326357A (en) | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
US5364845C1 (en) | 1993-03-31 | 2002-09-10 | Nutramax Lab Inc | Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue |
US5639740A (en) | 1995-03-10 | 1997-06-17 | Crandall; Wilson Trafton | Topical moisturizing composition and method |
US5840715A (en) | 1995-12-11 | 1998-11-24 | Inholtra Investment Holdings & Trading, N.V. | Dietary regimen of nutritional supplements for relief of symptoms of arthritis |
US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5877212A (en) * | 1997-04-16 | 1999-03-02 | Yu; Ruey J. | Molecular complex and control-release of alpha hydroxyacids |
-
1999
- 1999-10-01 US US09/410,868 patent/US6482401B1/en not_active Expired - Fee Related
-
2002
- 2002-09-30 US US10/261,207 patent/US20030045503A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007808B1 (en) * | 2004-10-12 | 2007-02-27 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Preparation for the treatment of joint diseases |
EA007809B1 (en) * | 2004-10-12 | 2007-02-27 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Preparation for the treatment of joint diseases |
WO2007087344A3 (en) * | 2006-01-25 | 2007-12-13 | Taro Pharmaceuticals Usa Inc | Anti-histamine compositions and use thereof |
US20090048268A1 (en) * | 2006-01-25 | 2009-02-19 | Taro Pharmaceuticals North America, Inc. | Anti-histamine compositions and use thereof |
US8569278B2 (en) | 2006-01-25 | 2013-10-29 | Taro Pharmaceuticals North America, Inc. | Anti-histamine compositions and use thereof |
WO2009007660A1 (en) | 2007-07-04 | 2009-01-15 | Mathieu Borge | Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation |
Also Published As
Publication number | Publication date |
---|---|
US6482401B1 (en) | 2002-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5503825A (en) | Lip balm composition | |
HUP9903544A2 (en) | Pharmaceutical composition with anaesthetic effect for local use | |
US6482401B1 (en) | Composition for the relief of joint pain and myofascial pain and method of preparing same | |
BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
CA2091200A1 (en) | Topical composition for relieving aches and pains | |
BR9714063A (en) | Compound, process for preparing and using same, pharmaceutical composition, and processes for preparing same, for performing immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease | |
US5853768A (en) | Topical preparation and method for pain relief | |
DE69908375T9 (en) | NIMESULIDE-CONTAINING TOPICAL MEDICINES | |
US5882663A (en) | Topical pain-relieving preparation containing C12 To C18 isoparaffins | |
KR970705998A (en) | 2-diaminopyrimidine 3-oxide or a salt thereof (USE OF 2,4-DIAMINO PYRIMIDINE 3-OXIDE OR A SALT THEREOF FOR TREATING COLLAGEN MATURATION AND STRUCTURING DISORDERS) | |
US6833139B1 (en) | Composition and method for the treatment of anorectal disorders | |
JPS5920217A (en) | Aqueous jellylike composition stably containing urea | |
JPH11269026A (en) | Low adhesive lotion, gel and cream | |
CA2376850A1 (en) | Topical formulations comprising skin penetration agents and the use thereof | |
US5886038A (en) | Composition and method for treatment of psoriasis | |
NZ504274A (en) | Topical water-in-oil anaesthetic formulation for use in pain management | |
US4602040A (en) | Meclofenamic acid topical pharmaceutical composition | |
WO1992013540A1 (en) | Antalgic ointment | |
RU2097032C1 (en) | Pharmaceutical preparation as cream | |
US20070141167A1 (en) | Use of Benzyl Nicotinate for Pain Relief | |
JPH03157311A (en) | Cosmetic for common acne | |
US5244880A (en) | Stable aqueous solutions of prymicin and pharmaceutical and cosmetic compositions containing these solutions | |
CH688760A5 (en) | A topical preparation for promotion of muscle growth. | |
EP0367586B1 (en) | Primycin solutions | |
GB2131693A (en) | Composition for local corticotherapy containing hydrocortisone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |